Introduction
============

Bladder cancer is one of the most common urinary malignancies accounting for 90%--95% of all urothelial carcinomas. The age-standardized incidence rate (per 100,000 person-years) of bladder cancer is 9.0 for men and 2.2 for women worldwide.[@b1-ott-11-6415] In the European Union, the age-standardized incidence rate is 12.8 for men and 4.0 for women.[@b1-ott-11-6415] Finally, the age-standardized incidence rate is 19.1 for men and 2.8 for women in Japan.[@b2-ott-11-6415] Moreover, there was an estimated 76,960 new cases (58,950 men and 18,010 women) of urinary bladder cancer diagnosed in the USA in 2016.[@b3-ott-11-6415] Despite advancement in treatment for bladder cancer in the past years, the 5-year overall survival (OS) rate remains unsatisfying, especially for metastatic bladder cancer.[@b1-ott-11-6415]--[@b3-ott-11-6415] As we know, the prognosis of bladder cancer is associated with the tumor stage, so seeking a novel diagnostic and prognostic biomarker is important for effective treatment.

Long non-coding RNAs (lncRNAs) belong to the ncRNA family, which are defined as transcripts longer than 200 nucleotides.[@b4-ott-11-6415] With the rapid development of cancer genomics, more and more lncRNAs have demonstrated important action in the initiation and development of tumors.[@b5-ott-11-6415] For example, HOTAIR was shown to be highly expressed in non-small-cell lung cancer (NSCLC), affecting tumorigenesis and metastasis of NSCLC.[@b6-ott-11-6415] Moreover, Srivastava et al found that lncRNCA UCA1 was overexpressed in bladder cancer and that elevated expression of UCA1 was positively associated with tumor grade. A further study suggested that UCA1 can be used as a noninvasive diagnostic biomarker in transitional cell carcinoma.[@b7-ott-11-6415] It is worth mentioning that the US Food and drug administration (FDA) has approved the prostate cancer antigen 3 (PCA3) clinical test to replace the previous prostate specific antigen (PSA) analysis. Because of the high specificity (SPE) and sensitivity (SEN) of PCA3 detection, it can be used to diagnose prostate cancer quickly and easily, which is superior to PSA.[@b8-ott-11-6415],[@b9-ott-11-6415]

However, most of the previously mentioned studies lack a sufficiently large sample size and have artificial errors, so it is recommended that they be combined and the potential clinical value of lncRNAs in bladder cancer be systematically analyzed. To date, no meta-analysis of the association between lncRNAs and bladder cancer has been published. Therefore, the present study is the first to systematically detail the relationship between lncRNAs and bladder cancer. In this study, results were organized to address three main topics: clinicopathological features, diagnosis, and prognosis. The essential lncRNAs described in this analysis may prove to be novel diagnostic and prognostic biomarkers for bladder cancer.

Materials and methods
=====================

Literature search
-----------------

Two of the authors (Jing Quan and Xiang Pan) each searched several databases, including PubMed, Embase, and the Cochrane Library, for studies of lncRNAs and bladder cancer. The publication dates used in the literature search was from database inception to November 1, 2017. The following search terms were used to retrieve articles and abstracts: (lncRNA OR lincRNA OR long non-coding RNA OR long untranslated RNA OR long non-protein-coding RNA OR long intergenic non-protein coding RNA) and (bladder cancer OR bladder neoplasm OR bladder tumor OR bladder urothelial carcinoma OR urinary bladder neoplasm OR cancer of the bladder OR malignant tumor of urinary bladder).

Inclusion and exclusion criteria
--------------------------------

All included studies met the following inclusion criteria: 1) study patients were diagnosed with bladder cancer by histopathology; 2) study investigated the association between the expression of lncRNAs and clinicopathological features; 3) the expression level of lncRNAs was divided into two levels: high or low; 4) sufficient data, including SEN, SPE, survival outcome, or HR, 95% CI and Kaplan--Meier curve, or if unavailable, related data obtained by contacting the corresponding authors.

Exclusion criteria were: 1) duplicate study; 2) study data incomplete or not of high quality; 3) study was a meeting report, review, meta-analysis article, animal or cell study; and 4) study included data from The cancer genome atlas (TCGA) database.

Extracted data and assessment of quality
----------------------------------------

Two independent authors (Jing Quan and Xiang Pan) collected the following information from the literature for each publication: author and publication year, region, type of lncRNA, expression, detected sample, test method, cut-off value, validation sample, number of cases, survival analysis, HR, and follow-up times. We assessed the quality of all the included diagnostic studies according to the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) criteria[@b10-ott-11-6415] and used the Newcastle-Ottawa Scale (NOS)[@b11-ott-11-6415] to assess the quality of the selected prognostic studies (score \>5 was regarded as high quality).

Statistical analysis
--------------------

Heterogeneity among studies was assessed by Cochran's *Q*-test and Higgin's *I*^2^ statistic. *P*\<0.05 or *I*^2^\>50% indicated that heterogeneity was considered statistically significant. To evaluate the relationship between lncRNA expression and survival outcomes, a fixed-effects or random-effects model was used. A random-effects model (Mantel--Haenszel test) was applied in the absence of between-study heterogeneity (*P≤*0.05 or *I*^2≥^50%). Otherwise, a fixed-effects model was used.[@b12-ott-11-6415] A different effect size was selected for each meta-analysis. 1) For the meta-analysis of clinicopathological features, the OR and associated 95% CI was used. 2) Meta-analysis of diagnosis, SEN, SPE, and area under curve (AUC) was used. 3) The HR and associated 95% CI for each study was used to estimate the survival outcomes associated with the expression of lncRNA. HR \>1 was regarded as a worse survival for the group with elevated lncRNA expression. STATA 14.0 software (StataCorp LP, College Station, TX, USA) was used to analyze study data and construct the forest plot. *P*\<0.05 was considered to be statistically significant.

Result
======

Study features
--------------

A total of 394 publication titles were downloaded from PubMed, Embase, and the Cochrane Library after using the relevant search terms. A total of **374** publication titles were downloaded from PubMed, Embase, and the Cochrane Library after using the relevant search terms. A total of **190** publications were excluded due to repetition; a further **129** publications were excluded based on their titles and abstracts. The remaining 55 full-text publications were retrieved. Subsequently, 25 of these studies were excluded for various reasons: including 13 without essential data, four focusing on other tumors, three with TCGA data, three with descriptions of genetic variation, and two more duplicate reports. In the end, 30 articles were eligible for this study. The present meta-analysis on lncRNA and bladder cancer analyzed 13 articles about clinicopathological characteristics,[@b13-ott-11-6415]--[@b25-ott-11-6415] six articles about diagnosis,[@b7-ott-11-6415],[@b26-ott-11-6415]--[@b30-ott-11-6415] and 16 articles about prognosis.[@b13-ott-11-6415],[@b15-ott-11-6415],[@b23-ott-11-6415],[@b28-ott-11-6415],[@b31-ott-11-6415]--[@b42-ott-11-6415] The study selection process is shown in [Figure 1](#f1-ott-11-6415){ref-type="fig"}.

Clinicopathological characteristics
-----------------------------------

After screening, 13 publications on clinicopathological characteristics were included. Except BANCR, most of the lncRNAs were overexpressed, including SPRY4-IT1, UBC1, ASAP1-IT1, PANDAR, ZEB1-AS1, ROR, MIT31HG, SUMO1P3, ABHD11-AS1, AATBC, CCAT2, and HIF1A-AS2. All were detected by RT-qPCR. The results ([Table 1](#t1-ott-11-6415){ref-type="table"}) demonstrated that lncRNA expression was not significantly associated with gender, age, and tumor size. Nine studies reported that lncRNAs were associated with histological grade, while almost all studies demonstrated that the abnormal expression of lncRNAs was related to tumor stage, except UBC1. Additionally, nearly all studies showed that lncRNAs were significantly correlated with tumor stage. Finally, there was a significant correlation observed between the up-regulation of lncRNA SPRY4-IT1, UBC1, and ROR and lymph node metastasis.

Diagnosis
---------

The QUADAS-2 scores of all included literature are presented in [Table 2](#t2-ott-11-6415){ref-type="table"}. The majority of the eight studies in the current meta-analysis met most items in QUADAS-2, suggesting that the overall quality of included studies was moderate to high. The present meta-analysis contained 725 patients with bladder cancer and 510 healthy controls. The meta-analysis result showed that significant heterogeneity between these studies was observed among SEN and SPE data (*I*^2^=95.42% and *I*^2^=93.33%, respectively). Therefore, the random effects model was used to calculate the pooled diagnostic parameters of the included studies. The pooled estimates of all included lncRNAs for the diagnosis of bladder cancer were as follows: SEN, 0.73 (95% CI, 0.58--0.84); SPE, 0.78 (95% CI, 0.62--0.89); positive likelihood ratio (PLR), 3.366 (95% CI, 1.58--7.15); negative likelihood ratio (NLR), 0.34 (95% CI, 0.19--0.63); and overall diagnostic OR (DOR), 11.58 (95% CI, 3.78--35.54). Finally, the corresponding summary receiver operator characteristic (SROC) curve with an AUC was 0.82 (95% CI, 0.78--0.85).

Due to the significant heterogeneity between these studies observed in SEN and SPE data (*I*^2^=95.42% and *I*^2^=93.33%, respectively), we constructed a meta-regression analysis including ethnicity and detected sample types. The result displayed that the detected sample types hardly affected the diagnostic accuracy for bladder cancer. By contrast, ethnicity significantly influenced SEN (*P*=0.02) but did not influence SPE. These results mean that lncRNA expression in an Asian population may exhibit a higher SEN in the diagnosis of bladder cancer. Importantly, there was no significant publication bias among the included studies (*P*=0.466).

Remarkably, UCA1 lncRNA was detected in five studies, therefore we performed a separate analysis of UCA1 for the diagnosis of bladder cancer. Our meta-analysis result showed significant heterogeneity between these studies in terms of SEN and SPE data (*I*^2^=36.72% and *I*^2^=88.88%, respectively). For this reason, the fixed effects model was used to calculate the pooled SEN parameters of the included studies and the random effects model was used to calculate the pooled SPE parameters of the included studies. As shown in [Figure 2](#f2-ott-11-6415){ref-type="fig"}, the pooled estimates of UCA1 in the diagnosis of bladder cancer were as follows: SEN, 0.83 (95% CI, 0.77--0.88); SPE, 0.87 (95% CI, 0.73--0.94); PLR, 6.14 (95% CI, 2.77--13.62); NLR, 0.20 (95% CI, 0.13--0.30); and DOR, 30.79 (95% CI, 9.77--97.03). Significant heterogeneity between these studies was observed in SPE data (*I*^2^=88.88%), however, meta-regression analysis could not be generated due to small size. [Figure 3](#f3-ott-11-6415){ref-type="fig"} shows SROC curve with an AUC of 0.88 (95% CI, 0.85--0.91). In this meta-analysis, Deeks' funnel plot asymmetry test was used to evaluate potential publication bias and, as shown in [Figure 4](#f4-ott-11-6415){ref-type="fig"}, no significant publication bias existed among the studies (*P*=0.335).

Prognosis
---------

In our analysis of prognosis, the NOS was used to assess the quality of the prognostic studies selected. The scores of all included studies were \>5 and regarded as high quality. The basic information from the 16 studies is summarized in [Table 3](#t3-ott-11-6415){ref-type="table"}. Within this analysis 16 lncRNAs were included. Among them, HOTAIR was detected in three studies, UBC1, TUG1, H19, and GAS5 were detected in two studies, and the rest were investigated in a single study. Interestingly, Droop et al[@b40-ott-11-6415] found that decreased expression of TUG1 was associated with poor prognosis, but a study by Iliev et al[@b39-ott-11-6415] reported that overexpression of TUG1 predicts poor prognosis. A similar contradiction was also observed regarding UBC1. Due to these contradictory reports, it was important to do a meta-analysis on the relationship between five lncRNAs' expression and the outcome of patients with bladder cancer. All results are displayed in [Table 4](#t4-ott-11-6415){ref-type="table"}.

Aberrant expression of all five lncRNAs required more evidence to make a definitive conclusion on OS, especially regarding TUG1 and UBC1. In addition, we found that HOTAIR was up-regulated in bladder cancer and the over-expression of HOTAIR was associated with poor disease-free survival/recurrence-free survival/disease-specific survival (DFS/RFS/DSS) (pooled HR =1.18, 95% CI, 2.17--3.76, *P*=0.006). Similarly, GAS5 was found to be downregulated in bladder cancer and such suppression of GAS5 was associated with a poor DFS/progression-free survival (PFS)/DSS (pooled HR =0.58, 95% CI, 0.41--0.84, *P*=0.003). However, the relationship between H19 and DFS/PFS/DSS remained tenuous and requires further investigation. Again, due to small sample size, we were not able to perform an SEN analysis of publication bias.

Discussion
==========

With deepening research, more and more evidence has proved that lncRNAs are closely associated with the initiation and development of cancers. Aberrant expression of lncRNAs affect many cellular processes, including proliferation, migration, invasion, and apoptosis. Further clinical findings demonstrated that aberrant expression of lncRNAs was related to the clinical outcomes of cancer patients. As one of the most common malignant tumors, the outcomes for bladder cancer are quite poor, with a 50% recurrence rate and 15%--40% developing into muscle-invasive disease.[@b43-ott-11-6415] This meta-analysis was designed to identify possible biomarkers for bladder cancer.

To analyze the relationship between lncRNA expression and clinical features of bladder cancer, 13 studies were included in our comprehensive systematic review. In this study, we found that no lncRNAs were significantly associated with gender, age, and tumor size. Additionally, almost all aberrant lncRNAs were associated with histological grade, including SPRY4-IT1, PANDAR, ZEB1-AS1, ROR, SUMO1P3, ABHD11-AS1, AATBC, CCAT2, and HIF1A-AS2. Nearly all studies demonstrated that lncRNAs were significantly correlated with tumor stage. Finally, our results showed a correlation between the up-regulation of lncRNA SPRY4-IT1, UBC1, and ROR and lymph node metastasis, which was significant. This finding might suggest that lncRNAs may be biomarkers for lymph node metastasis. However, this conclusion should be further verified due to limitation within the included studies.

There is a lack of a satisfactory method to diagnose bladder cancer. Until now, cystoscopy screening, random bladder biopsies, and voided urinary cytology remain the most commonly used methods for the initial diagnosis of bladder cancer. However, the former two methods are invasive and uncomfortable, and the latter method has a low SEN for the detection of bladder cancer.[@b44-ott-11-6415],[@b45-ott-11-6415] For these reasons, identification of a highly sensitive, highly specific, and non-invasive method to detect bladder cancer is necessary. In this meta-analysis, we found that lncRNAs are expected to be diagnostic biomarkers for bladder cancer, especially UCA1.

A meta-analysis was executed to assess the diagnostic ability of UCA1. The results of pooled estimates of UCA1 in the diagnosis of bladder cancer were as follows: SEN, 0.83 (95% CI, 0.77--0.88), SPE, 0.87 (95% CI, 0.73--0.94), and SROC curve with an AUC of 0.88 (95% CI, 0.85--0.91). This result suggested that UCA1 was a satisfactory diagnostic biomarker for bladder cancer. Compared with single lncRNA, a combination of several lncRNAs might be more suitable to diagnose bladder cancer. Duan et al found that the diagnostic performance of the lncRNA panel (MEG3, SNHG16, and MALAT1) for Ta, T1, and T2--T4 was significantly higher than that of urine cytology respectively.[@b28-ott-11-6415] Bao et al also found that a four-lncRNA panel could be a novel independent biomarker for predicting survival in patients with bladder cancer, independent of other clinical variables. Further results showed that these four prognostic lncRNAs may be involved in known bladder cancer-related biological processes and pathways.[@b46-ott-11-6415]

Regarding prognostic value, the present study contained analysis of 16 aberrant lncRNAs, including six up-regulated lncRNAs, seven downregulated lncRNAs, and three controversial lncRNAs. However, only five lncRNAs were repeatedly reported. Additionally, we conducted a meta-analysis to analyze the association between lncRNA expression and the prognosis of patients with bladder cancer. As a result, it was observed that HOTAIR was up-regulated in bladder cancer and the overexpression of HOTAIR was associated with poor DFS/RFS/DSS, while GAS5 was downregulated in bladder cancer and the suppressed expression of GAS5 was associated with poor DFS/PFS/DSS. This result is similar in other tumors. Shen et al found that overexpression of HOTAIR was associated with lower OS/DFS and high levels of GAS5 were associated with better OS/DFS in patients with glioblastoma.[@b47-ott-11-6415] Cui et al also displayed that HOTAIR and GAS5 levels in tissues could act as predictors of survival in patients with cervical cancer, by meta-analysis.[@b48-ott-11-6415] However, the result showed that there was no statistical significance between three controversial lncRNAs' expression (TUG1, UBC1, and H19) and the prognosis of patients with bladder cancer. Therefore, to verify the relationship, more evidence is needed.

Several limitations to this study should be considered. Firstly, the number of studies included in the meta-analysis was less than desirable. Data on individual lncRNAs appeared only once among the incorporated studies and few lncRNAs appeared in more than two different studies; a fact which would influence the sample heterogeneity. Secondly, different sample types (tissue, serum, and urine) and different follow-up times used in the studies induced heterogeneity. Certainly, the cut-off value and method of determining low or high levels of lncRNAs varied between different studies; and although RT-qPCR was used as the standard method to evaluate the expression of lncRNAs, this also might have caused heterogeneity of the results. To improve comparability among studies, researchers should develop a cut-off value with enhanced consistency and establish a standard method to classify high or low lncRNA expression. Thirdly, we extracted HR and 95% CI values from Kaplan--Meier curve according to Tierney's methodology, due to lack of survival data, which may have caused potential heterogeneity.[@b49-ott-11-6415] Fourthly, because most of the selected literature came from China, the conclusions drawn from the subgroup analysis on ethnicity need further verification. As for publication bias, language bias existed because only English publications were included in this study and no studies with negative results were published, perhaps leading to overestimated pooled effect value.

Conclusion
==========

Taken together, the present study is the first meta-analysis to assess the expression of lncRNAs and their clinical value in patients with bladder cancer. As a result, several specific lncRNAs were identified to be significantly associated with the prognosis of patients with bladder cancer, and could potentially be used as predictive biomarkers for patient survival. Among them, UCA1 was expected to be a diagnostic biomarker for bladder cancer, while the aberrant expression of HOTAIR and GAS5 was associated with poor DFS/RFS/DSS. However, further large-scale studies should be carried out to confirm our findings and to verify the clinical value of lncRNAs in bladder cancer.
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###### 

The association between lncRNAs and clinicopathological features

  Study                                Region   LncRNA       Simple size (n)   Age     Gender   Tumor size (cm)   Histological grade (I--IV)   Tumor stage (T1--T4)   Lymph node metastasis   Detection method   Expression
  ------------------------------------ -------- ------------ ----------------- ------- -------- ----------------- ---------------------------- ---------------------- ----------------------- ------------------ ----------------
  He et al, 2013[@b13-ott-11-6415]     China    UBC1         102               0.961   0.655    NA                NA                           0.422                  0.021                   RT-qPCR            Up-regulation
  Zhao et al, 2015[@b14-ott-11-6415]   China    AATBC        90                0.863   0.899    NA                0.010                        0.015                  0.315                   RT-qPCR            Up-regulation
  Zhao et al, 2015[@b15-ott-11-6415]   China    SPRY4-IT1    68                0.790   0.707    0.874             0.000                        0.017                  0.000                   RT-qPCR            Up-regulation
  Zhan et al, 2016[@b16-ott-11-6415]   China    PANDAR       55                0.745   0.953    0.061             0.010                        0.027                  0.607                   RT-qPCR            Up-regulation
  He et al, 2016[@b17-ott-11-6415]     China    MIT31HG      55                0.607   0.415    0.109             0.415                        0.010                  0.114                   RT-qPCR            Up-regulation
  Zhan et al, 2016[@b18-ott-11-6415]   China    SUMO1P3      55                0.580   0.528    0.114             0.005                        0.037                  0.618                   RT-qPCR            Up-regulation
  Chen et al, 2016[@b19-ott-11-6415]   China    ABHD11-AS1   66                0.578   0.575    NA                0.001                        0.001                  0.663                   RT-qPCR            Up-regulation
  He et al, 2016[@b20-ott-11-6415]     China    BANCR        54                0.230   0.09     0.065             0.194                        0.004                  0.559                   RT-qPCR            Downregulation
  Li et al, 2016[@b21-ott-11-6415]     China    CCAT2        48                0.750   0.771    0.763             0.014                        0.016                  0.563                   RT-qPCR            Up-regulation
  Chen et al, 2016[@b22-ott-11-6415]   China    HIF1A-AS2    44                0.748   0.091    0.501             0.003                        ,0.001                 0.540                   RT-qPCR            Up-regulation
  Yang et al, 2017[@b23-ott-11-6415]   China    ASAP1-IT1    58                0.790   1.000    NA                NA                           0.014                  0.160                   RT-qPCR            Up-regulation
  Lin et al, 2017[@b24-ott-11-6415]    China    ZEB1-AS1     55                0.745   0.792    0.940             0.001                        0.027                  1.000                   RT-qPCR            Up-regulation
  Chen et al, 2017[@b25-ott-11-6415]   China    ROR          36                0.289   1.000    NA                0.000                        0.000                  0.000                   RT-qPCR            Up-regulation

**Abbreviations:** lncRNA, long non-coding RNA; NA, not available.

###### 

Summary of lncRNAs used as prognostic biomarkers of bladder cancer

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                               Region     LncRNA      Expression        Detected sample   Test method   Cut-off    Sample size   Survival analysis   HR availability   Follow-up month   NOS    
  --------------------------------------------------- ---------- ----------- ----------------- ----------------- ------------- ---------- ------------- ------------------- ----------------- ----------------- ------ ---
  Ariel et al, 2000[@b31-ott-11-6415]                 Israel     H19         Up-regulation     Tissue            RT-qPCR       NA         16            14                  OS                Indirectly        80     5

  Wang et al, 2013[@b13-ott-11-6415]                  China      UBC1        Up-regulation     Tissue            RT-qPCR       FC \>1.5   60            42                  OS\               Indirectly\       80     5
                                                                                                                                                                            MFS               Indirectly               

  Li et al, 2014[@b32-ott-11-6415]                    China      GHET1       Up-regulation     Tissue            RT-qPCR       Median     39            41                  OS                Indirectly        60     6

  Zhao et al, 2015[@b15-ott-11-6415]                  China      SPRY4-IT1   Downregulation    Tissue            RT-qPCR       Mean       38            30                  OS                Directly          NA     5

  Martínez- Fernández et al, 2015[@b33-ott-11-6415]   Spain      HOTAIR      Up-regulation     Tissue            RT-qPCR       Median     30            33                  PFS\              Indirectly\       36\    5
                                                                                                                                                                            OS                Indirectly        72     

  Chen et al, 2015[@b34-ott-11-6415]                  China      n336928     Up-regulation     Tissue            RT-qPCR       FC \>2     44            51                  OS                Directly          60     5

  Heubach et al, 2015[@b35-ott-11-6415]               Germany    HOTAIR      Up-regulation     Tissue            RT-qPCR       FC \>2     27            81                  DSS               Directly          200    6

  Duan et al, 2016[@b28-ott-11-6415]                  China      MEG3        Downregulation    Serum             RT-qPCR       NA         26            33                  RFS               Indirectly        57     7

  Zhang et al, 2016[@b36-ott-11-6415]                 China      UNMIBC      Up-regulation     Tissue            RT-qPCR       FC \>1.5   42            33                  RFS               Directly          36     6

  Zhang et al, 2016[@b37-ott-11-6415]                 China      GAS5        Downregulation    Tissue            RT-qPCR       Median     41            41                  DFS               Directly          60     7

  Shang et al, 2016[@b38-ott-11-6415]                 China      HOTAIR      Up-regulation     Tissue            RT-qPCR       NA         16            19                  OS                Indirectly        40     5

  Iliev et al, 2016[@b39-ott-11-6415]                 Czech\     TUG1        Up-regulation     Tissue            RT-qPCR       NA         26            21                  OS                Directly          100    
                                                      Republic                                                                                                                                                         

  Yan et al, 2017[@b23-ott-11-6415]                   China      ASAP1-IT1   Up-regulation     Tissue            RT-qPCR       Median     19            19                  OS                Directly          44     6

  Droop et al, 2017[@b40-ott-11-6415]                 Germany    MALAT1\     Downregulation\   Tissue            RT-qPCR       Median     53            53                  OS\               Directly\         200\   6
                                                                 TUG1\       Downregulation\                                                                                DSS               Directly          200    
                                                                 UCA1\       Downregulation\                                                                                                                           
                                                                 UBC1\       Downregulation\                                                                                                                           
                                                                 NcRAN\      Downregulation\                                                                                                                           
                                                                 GAS5\       Downregulation\                                                                                                                           
                                                                 H19         Downregulation                                                                                                                            

  Wang et al, 2017[@b41-ott-11-6415]                  China      HULC        Up-regulation     Tissue            RT-qPCR       Median     138           138                 RFS               Indirectly        14     5

  Zhuang et al, 2017[@b42-ott-11-6415]                China      LET         Downregulation    Tissue            RT-qPCR       Median     30            30                  OS                Indirectly        48     6
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** DFS, disease-free survival; DSS, disease-specific survival; FC, fold change; lncRNA, long non-coding RNA; MFS, metastasis-free survival; NOS, Newcastle-Ottawa Scale; OS, overall survival; PFS, progression-free survival; RFS, recurrence-free survival.

###### 

Summary of lncRNAs used as diagnostic biomarkers of bladder cancer

  Study                                     Region    LncRNA   Expression       SEN (%)   SPE (%)   AUC     Sample size   Detected sample   QUADAS-2   
  ----------------------------------------- --------- -------- ---------------- --------- --------- ------- ------------- ----------------- ---------- ---
  Wang et al, 2006[@b26-ott-11-6415]        China     UCA1     Up-regulation    91.60     81.30     0.882   94            85                Urine      6
  Srivastava et al, 2014[@b7-ott-11-6415]   India     UCA1     Up-regulation    79.49     79.73     0.863   117           74                Urine      5
  Milowich et al, 2015[@b30-ott-11-6415]    Belgium   UCA1     Up-regulation    70        70.7      NA      69            93                Urine      5
  Eissa et al, 2015[@b27-ott-11-6415]       Egypt     UCA1     Up-regulation    91.50     96.50     0.975   94            116               Urine      6
  Duan et al, 2016[@b28-ott-11-6415]        China     MEG3     Downregulation   70.00     75.80     0.798   120           52                Serum      6
  Duan et al, 2016[@b28-ott-11-6415]        China     SNHG16   Up-regulation    64.20     65.00     0.687   120           52                Serum      5
  Duan et al, 2016[@b28-ott-11-6415]        China     MALAT1   Up-regulation    56.70     67.50     0.640   120           52                Serum      5
  Xue et al, 2017[@b29-ott-11-6415]         China     UCA1     Up-regulation    80.00     83.33     0.878   30            30                Serum      5

**Abbreviations:** lncRNAs, long non-coding RNAs; QUADAS-2, Quality Assessment of Diagnostic Accuracy Studies-2; SEN, sensitivity; SPE, specificity.

###### 

The relationship between five lncRNAs and the survival of patients with bladder cancer

  lncRNA         Number of studies   Test of association   Test of heterogeneity                               
  -------------- ------------------- --------------------- ----------------------- ------- ---- ------ ------- -------
  HOTAIR                                                                                                       
   OS            1                   1.18 (0.21--6.77)     --                      --      --   --     --      --
   RFS/DFS/DSS   2                   2.17 (1.25--3.76)     2.75                    0.006   R    0.03   0.868   0.00
  TUG1                                                                                                         
   OS            2                   1.16 (0.27--4.94)     0.21                    0.838   F    9.89   0.002   89.90
   RFS/DFS/DSS   1                   0.59 (0.36--0.97)     --                      --      --   --     --      --
  UBC1                                                                                                         
   OS            2                   0.96 (0.64--1.46)     0.17                    0.862   R    0.03   0.855   0.00
   RFS/DFS/DSS   1                   0.97 (0.59--1,59)     --                      --      --   --     --      --
  GAS5                                                                                                         
   OS            1                   0.71 (0.46--1.09)     --                      --      --   --     --      --
   RFS/DFS/DSS   2                   0.58 (0.41--0.84)     2.92                    0.003   R    0.99   0.349   0.00
  H19                                                                                                          
   OS            1                   0.90 (0.59--1.39)     --                      --      --   --     --      --
   RFS/DFS/DSS   2                   0.93 (0.58--1.49)     0.30                    0.762   R    0.00   0.953   0.00

**Abbreviations:** DFS, disease-free survival; DSS, disease-specific survival; lncRNA, long non-coding RNA; OS, overall survival; RFS, recurrence-free survival; R, random-effects model; F, fixed-effects model.
